Pure Global
NCT06363006

Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

Evaluation of the Efficacy and Safety of Cardonilimab Injection Combined With TKI as Second-line Treatment for Advanced Hepatocellular Carcinoma: A Single-arm, Open-label, Multicenter Real-world Clinical Study
Peking Union Medical College Hospital·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatocellular Carcinoma
Drug/Device/Intervention
TKI+Cardunilimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Peking Union Medical College Hospital
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Mar 11, 2024
End date
Jan 01, 2027
Enrollment
40 participants
Primary outcome

ORR Full single-arm, open, multicenter prospective clinical study,Progression-free Survival (PFS)

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab
 injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma.
 The main questions it aims to answer are:
 
 - Objective response rate (ORR) for evaluation
 
 - Disease Control Rate (DCR); Duration of relief (DoR); Progression free survival (PFS);
 Total survival time (OS); Safety。

ICD-10 classifications
Malignant neoplasm: HepatoblastomaMalignant neoplasm: Liver cell carcinomaMalignant neoplasm: Other specified carcinomas of liverMalignant neoplasm: Liver, unspecifiedMalignant neoplasm: Hepatic flexure
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06363006
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06363006 through Pure Global AI's free database. This Phase 1 trial is sponsored by Peking Union Medical College Hospital and is currently Recruiting. The study focuses on Hepatocellular Carcinoma. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.